[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocysticercosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocysticercosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100608984","the-impact-of-medical-tv-drama-in-improving-literacy-on-neurocysticercosis-100608984",false,"NCT07208656","The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis","The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis: An Online Open-Label Two-Arm Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 35 years\n* Proficient in English (reading and comprehension)\n* Has access to a stable internet connection\n* Possesses a screen-enabled device (e.g., smartphone, tablet, or computer)\n* Has access to the Netflix streaming platform\n\nExclusion Criteria:\n\n* Has formal education in medical or health sciences\n* Has a prior diagnosis of neurocysticercosis (NCC)\n* Has previously participated in any NCC-related health literacy or awareness program\n* Lacks access to the Netflix movie platform\n* Below 18 years or above 35 years of age",true,"ALL","18 Years","35 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled trial evaluates whether exposure to a medical television drama improves knowledge of neurocysticercosis (NCC) among young adults. Sixty participants aged 18-35 will be randomly assigned to either an intervention group, which will watch a medically relevant TV episode (House M.D., Season 1, Episode 1), or a control group with no media exposure. Both groups will complete pre- and post-test questionnaires assessing knowledge of NCC. The primary outcome is change in NCC-related knowledge. Secondary outcomes include motivation to seek further health information and perceived credibility of the media source",[28,29,30],"Neurocysticercosis","Health Literacy","Epilepsy","NOT_YET_RECRUITING","2025-11-26",{"date":34,"type":35},"2025-12-04","ACTUAL",{"date":37,"type":22},"2025-12-15",{"date":39,"type":22},"2026-04-15",{"name":41,"class":42},"Cephas Health Research Initiative Inc, Ibadan, Nigeria","NETWORK",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100545015","phase-4-assessment-of-combined-praziquantel-and-albendazole-vs-albendazole-alone-to-treat-active-parenchymal-neurocysticercosis-100545015","NCT06376396","Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis","Assessment of Combined Antiparasitic Drugs Praziquantel and Albendazole Versus Albendazole Alone in the Treatment of Active Parenchymal Neurocysticercosis in Tanzania and Zambia","NeuroSolve","Inclusion Criteria:\n\n* Living in the study area for a continuous period of 3 years\n* Adult aged 18 years and above\n* Are willing and able to consent to this study\n* Meet the definitions of active symptomatic NCC\n* Have late onset of epilepsy or history of seizures, epileptic seizures\n* Subjects willing to undergo diagnostic procedures\n* Subjects medically stable enough for trial medication to be initiated\n* Subjects willing to be hospitalized for 11-20 days to receive treatment for NCC\n* Subjects willing to be followed up for one year following receipt of study medication\n\nExclusion Criteria:\n\n* Women pregnant or breastfeeding\n* Symptomatic NCC with cysts in extra-parenchymal location (sub-arachnoid and\u002For ventricles)\n* Have uncontrolled hypertension and\u002For diabetes\n* Have chronic consuming illness such as cancer or mental handicap to not allow them to follow the study instructions\n* Have severe immunodeficiency eg. HIV\u002FAIDS or Autoimmune diseases\n* Already known allergies to albendazole or praziquantel\n* Subject taking part in another clinical\u002Fpharmacological study in the 30 days preceding enrollment",{"count":52,"type":22},300,[54],"PHASE4","The goal of this clinical trial is to compare the combination albendazole and praziquantel versus albendazole alone in patients affected by neurocysticercosis.",[28],[58,30],"Neglected Tropical Disease","2024-04-19",{"date":61,"type":35},"2024-04-23",{"date":63,"type":22},"2024-06",{"date":65,"type":22},"2026-12",{"name":67,"class":68},"R-Evolution Worldwide S.r.l. Impresa Sociale","OTHER"]